Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6818603 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL6821915 | 0.99 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL6822509 | 0.96 | HPGD (0.43) | SMN1; SMN2CYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL6822277 | 0.93 | HTT (0.40) | SMN1; SMN2ALDH1A1HTTLMNAADORA1 | |
| SCHEMBL6821408 | 0.88 | KMT2A (0.43) | SMN1; SMN2ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL6822503 | 0.86 | ADORA1 (0.41) | SMN1; SMN2ALDH1A1LMNAADORA1 | |
| SCHEMBL6821896 | 0.86 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP3A4ALDH1A1KMT2AMEN1 | |
| SCHEMBL6818702 | 0.85 | ADORA1 (0.46) | HTTADORA1 | |
| SCHEMBL6821443 | 0.85 | LMNA (0.43) | ALDH1A1KMT2AMEN1LMNAADORA1 | |
| SCHEMBL6822276 | 0.85 | ADORA1 (0.46) | ALDH1A1KMT2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | SMN1; SMN2 274/4885CYP1A2 373/4885CYP3A4 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.